US6083903A
(en)
*
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
ATE240113T1
(de)
*
|
1997-02-15 |
2003-05-15 |
Millennium Pharm Inc |
Behandlung von infarkten durch inhibierung von nf-kappab
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
AU9580098A
(en)
*
|
1997-09-25 |
1999-04-12 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
|
ATE357509T1
(de)
*
|
1997-09-29 |
2007-04-15 |
Point Therapeutics Inc |
Stimulierung von hämatopoietischen zellen im vitro
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
*
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6462019B1
(en)
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6902721B1
(en)
*
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(de)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalente Proteasome Inhibitore
|
KR20010080267A
(ko)
*
|
1998-10-20 |
2001-08-22 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
프로테아솜 억제제 약물 작용을 모니터링하는 방법
|
US6492333B1
(en)
*
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
US20040039129A1
(en)
*
|
2000-08-16 |
2004-02-26 |
Hall Dennis G. |
Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
CA2425632A1
(en)
*
|
2000-10-12 |
2002-04-18 |
Viromics Gmbh |
Agents for the treatment of viral infections
|
ES2359391T3
(es)
|
2001-01-25 |
2011-05-23 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Formulación de compuestos de acido boronico.
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
ES2278049T3
(es)
|
2001-05-21 |
2007-08-01 |
Alcon, Inc. |
Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
|
JP4416501B2
(ja)
|
2001-05-30 |
2010-02-17 |
ノバルティス アクチエンゲゼルシャフト |
2−{[n−(2−アミノ−3−(ヘテロアリールまたはアリール)プロピオニル)−アミノアシル]−アミノ}−アルキルボロン酸誘導体
|
WO2003033507A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
|
WO2003033506A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
|
AU2003219652A1
(en)
*
|
2002-01-08 |
2003-07-30 |
Eisai Co. Ltd. |
Eponemycin and epoxomicin analogs and uses thereof
|
EP1487459A4
(de)
*
|
2002-03-12 |
2006-05-24 |
Ariad Pharma Inc |
Peptid-analoga und ihre verwendung
|
KR20040090981A
(ko)
|
2002-03-13 |
2004-10-27 |
얀센 파마슈티카 엔.브이. |
신규한 히스톤 디아세틸라제 저해제로서의카보닐아미노-유도체
|
OA12793A
(en)
|
2002-03-13 |
2006-07-10 |
Janssen Pharmaceutica Nv |
Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
|
WO2003076438A1
(en)
*
|
2002-03-13 |
2003-09-18 |
Janssen Pharmaceutica N.V. |
Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
|
CA2476296C
(en)
*
|
2002-03-13 |
2011-02-22 |
Janssen Pharmaceutica N.V. |
Amino-derivatives as inhibitors of histone deacetylase
|
US20050203029A1
(en)
*
|
2002-04-05 |
2005-09-15 |
Ulrich Schubert |
Agents for treating <I>flaviviridae</I>infections
|
WO2003106384A2
(en)
*
|
2002-06-01 |
2003-12-24 |
Johns Hopkins University |
Novel boronic chalcone derivatives and uses thereof
|
CA2491466A1
(en)
*
|
2002-07-09 |
2004-01-15 |
Sharlene Adams |
Methods and compositions relating to isoleucine boroproline compounds
|
EP1536777B1
(de)
*
|
2002-08-14 |
2007-02-14 |
Janssen Pharmaceutica N.V. |
Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung
|
PT1396270E
(pt)
*
|
2002-09-09 |
2006-08-31 |
Trigen Ltd |
Processo para a preparacao de compostos uteisncomo intermidiarios.
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
US7112572B2
(en)
*
|
2002-09-09 |
2006-09-26 |
Trigen Limited |
Multivalent metal salts of boronic acids
|
EP1542768A1
(de)
*
|
2002-09-20 |
2005-06-22 |
Alcon, Inc. |
Verwendung von zytokin-synthesehemmern zur behandlung von erkrankungen mit trockenem auge
|
AU2003298873B2
(en)
|
2002-12-06 |
2011-09-01 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
US20070110785A1
(en)
*
|
2003-07-03 |
2007-05-17 |
Eugene Tedeschi |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
WO2005044998A2
(en)
|
2003-11-05 |
2005-05-19 |
Palingen, Inc. |
Enhanced b cell cytotoxicity of cdim binding antibody
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
MXPA06009589A
(es)
*
|
2004-02-23 |
2007-03-26 |
Tufts College |
Inhibidores de dipeptidil peptidasa iv par regular el metabolismo de glucosa.
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
NZ550522A
(en)
*
|
2004-03-30 |
2010-08-27 |
Millennium Pharm Inc |
Synthesis of boronic ester and acid compounds
|
PL1745064T3
(pl)
|
2004-04-15 |
2011-06-30 |
Onyx Therapeutics Inc |
Związki do hamowania enzymu proteazomu
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
CA2565407A1
(en)
|
2004-05-10 |
2005-11-24 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
EP2277595A3
(de)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Verbindungen zur Immunopotenzierung
|
ATE553077T1
(de)
|
2004-07-23 |
2012-04-15 |
Nuada Llc |
Peptidaseinhibitoren
|
SG156687A1
(en)
|
2004-07-28 |
2009-11-26 |
Janssen Pharmaceutica Nv |
Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
EP1805208A2
(de)
|
2004-10-20 |
2007-07-11 |
Proteolix, Inc. |
Markierte verbindungen zur proteasomhemmung
|
DK1814913T3
(en)
|
2004-11-05 |
2015-09-28 |
Univ Leland Stanford Junior |
ANTIBODY-INDUCED CELL membrane damage.
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
MX2007008781A
(es)
|
2005-01-21 |
2007-09-11 |
Astex Therapeutics Ltd |
Compuestos farmaceuticos.
|
US20090018146A1
(en)
*
|
2005-01-27 |
2009-01-15 |
Research Development Corporation |
Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
EP2987796B1
(de)
|
2005-02-16 |
2018-08-08 |
Anacor Pharmaceuticals, Inc. |
Halogen-substituierte boronophthalide zur behandlung von infektionen
|
US7589066B2
(en)
*
|
2005-03-11 |
2009-09-15 |
The University Of North Carolina At Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
EP1874297A4
(de)
*
|
2005-04-29 |
2009-04-22 |
Kosan Biosciences Inc |
Verfahren zur behandlung mehrerer myelome mithilfe von 17-aag oder 17-ag oder eines prodrugs oder von allem in kombination mit einem proteasom-hemmer
|
CA2605272C
(en)
|
2005-05-18 |
2013-12-10 |
Janssen Pharmaceutica N.V. |
Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
DK1888123T3
(da)
*
|
2005-06-08 |
2013-04-15 |
Janssen Biotech Inc |
Celleterapi til øjendegeneration
|
WO2007002972A2
(en)
*
|
2005-07-06 |
2007-01-11 |
Biodevelops Pharma Entwicklung Gmbh |
Use of a compound for enhancing the expression of membrane proteins on the cell surface
|
EP1752467A1
(de)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Krebszellen-, t-Zellen- und Keratinocyte-Proliferation-Inhibitoren
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
BRPI0618468A2
(pt)
*
|
2005-11-09 |
2011-08-30 |
Proteolix Inc |
compostos para inibição de enzima
|
EP1956908A2
(de)
*
|
2005-12-08 |
2008-08-20 |
Cytokinetics, Inc. |
Gewisse zusammensetzungen und behandlungsverfahren
|
RU2008131324A
(ru)
*
|
2005-12-30 |
2010-02-10 |
Анакор Фармасьютикалз, Инк. (Us) |
Борсодержащие малые молекулы
|
WO2007082874A1
(en)
*
|
2006-01-19 |
2007-07-26 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
RS51191B
(sr)
*
|
2006-01-19 |
2010-10-31 |
Janssen Pharmaceutica N.V. |
Derivati aminofenila kao novi inhibitori histon deacetilaze
|
EP1981875B1
(de)
*
|
2006-01-19 |
2014-04-16 |
Janssen Pharmaceutica N.V. |
Substituierte indolyl-amino-alkyl-derivate als histon-deacetylase-inhibitoren
|
US8101616B2
(en)
*
|
2006-01-19 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
ME02188B
(me)
|
2006-02-16 |
2016-02-20 |
Anacor Pharmaceuticals Inc |
Mali molekuli koji sadrže boron kao antiinflamatorni agensi
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US8741643B2
(en)
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
WO2007143600A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
WO2007149512A2
(en)
|
2006-06-19 |
2007-12-27 |
Proteolix, Inc. |
Peptide epoxyketones for pr0teas0me inhibition
|
PL2066327T3
(pl)
*
|
2006-09-15 |
2013-03-29 |
Janssen Pharmaceutica Nv |
Inhibitory deacetylaz histonowych o działaniu skojarzonym na deacetylazy histonowe klasy I oraz klasy IIB w kombinacji z inhibitorami proteasomu
|
BRPI0716838A2
(pt)
*
|
2006-09-15 |
2013-10-01 |
Janssen Pharmaceutica Nv |
combinaÇÕes de inibidores de histona deacetilase especÍfica de classe i com inibidores de proteosome
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
CA2606634A1
(en)
*
|
2006-12-08 |
2008-06-08 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
CN101952415B
(zh)
|
2007-07-31 |
2017-06-27 |
生命扫描有限公司 |
人胚胎干细胞的分化
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
JP2010535708A
(ja)
|
2007-08-03 |
2010-11-25 |
ビオマリン アイジーエー リミテッド |
デュシェンヌ型筋ジストロフィーの治療のための薬物併用
|
EP2178888B1
(de)
*
|
2007-08-06 |
2012-07-04 |
Millennium Pharmaceuticals, Inc. |
Proteasominhibitoren
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US7442830B1
(en)
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
MX2010002836A
(es)
*
|
2007-09-12 |
2010-03-31 |
Reddys Lab Ltd Dr |
Bortezomib y proceso para la produccion del mismo.
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
MY166950A
(en)
|
2007-10-04 |
2018-07-25 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
CA2954431C
(en)
*
|
2007-11-27 |
2021-08-24 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells to pancreatic cells
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
AU2008340053A1
(en)
|
2007-12-20 |
2009-07-02 |
Novartis Ag |
Thiazole derivatives used as PI 3 kinase inhibitors
|
US10066203B2
(en)
|
2008-02-21 |
2018-09-04 |
Janssen Biotech Inc. |
Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
|
AU2009221793B2
(en)
|
2008-03-06 |
2015-02-19 |
Anacor Pharmaceuticals, Inc |
Boron-containing small molecules as anti-inflammatory agents
|
WO2009140309A2
(en)
*
|
2008-05-12 |
2009-11-19 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
GEP20135847B
(en)
|
2008-06-17 |
2013-06-10 |
Millennium Pharm Inc |
Boronate ester compounds and pharmaceutical compositions containing them
|
RU2533805C2
(ru)
|
2008-06-30 |
2014-11-20 |
Сентокор Орто Байотек Инк. |
Дифференцирование плюрипотентных стволовых клеток, представляющих собой линию клеток человека
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
WO2010027975A1
(en)
*
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
US8461336B2
(en)
|
2008-09-04 |
2013-06-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
WO2010045503A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
EP3090737A1
(de)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Kombinationstherapie mit peptidepoxyketonen
|
ES2727950T3
(es)
|
2008-10-31 |
2019-10-21 |
Janssen Biotech Inc |
Diferenciación de células madre embrionarias humanas en linaje endocrino pancreático
|
WO2010051223A1
(en)
|
2008-10-31 |
2010-05-06 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
|
AU2009316583B2
(en)
*
|
2008-11-20 |
2016-04-21 |
Janssen Biotech, Inc. |
Methods and compositions for cell attachment and cultivation on planar substrates
|
WO2010059775A1
(en)
|
2008-11-20 |
2010-05-27 |
Centocor Ortho Biotech Inc. |
Pluripotent stem cell culture on micro-carriers
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
BRPI0922566A2
(pt)
*
|
2008-12-17 |
2017-03-28 |
Anacor Pharmaceuticals Inc |
polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
|
WO2010089768A2
(en)
|
2009-01-09 |
2010-08-12 |
Sun Pharma Advanced Research Company Limited |
Pharmaceutical composition
|
EP2399129B1
(de)
|
2009-02-20 |
2015-11-25 |
Michael P. Lisanti |
Verfahren zur diagnose bzw. prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma
|
WO2010105008A2
(en)
|
2009-03-12 |
2010-09-16 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
DK2411535T3
(en)
*
|
2009-03-24 |
2015-07-13 |
Janssen Pharmaceutica Nv |
BIOMAR RUNNING FOR ASSESSMENT OF PERIPHERAL NEUROPATHY RESPONSE TO TREATMENT WITH a proteasome inhibitor
|
CN103932972A
(zh)
*
|
2009-03-30 |
2014-07-23 |
天蓝制药公司 |
聚合物-药剂缀合物、颗粒、组合物和相关使用方法
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
AU2009347159B2
(en)
*
|
2009-05-27 |
2015-09-03 |
Cephalon, Inc. |
Combination therapy for the treatment of multiple myeloma
|
EP2280016A1
(de)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
Neue synthetische Route zur Herstellung von Alpha-Aminoborestern über substituierte Alylene
|
EP2270019A1
(de)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
Neue synthetische Route zur Herstellung von alpha-Aminoborestern
|
CN102803271B
(zh)
|
2009-06-19 |
2016-03-23 |
力奇制药公司 |
氢化卤代烯烃而不脱卤的方法
|
CN101928329B
(zh)
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
RU2540021C2
(ru)
*
|
2009-07-20 |
2015-01-27 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека
|
RU2579278C2
(ru)
|
2009-07-20 |
2016-04-10 |
Янссен Байотек, Инк. |
Популяция панкреатических эндокринных клеток-предшественников для снижения концентрации глюкозы в крови и способ дифференцировки панкреатических эндодермальных клеток
|
CA2768720C
(en)
|
2009-07-20 |
2018-12-18 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
BR112012001987A2
(pt)
*
|
2009-07-28 |
2015-09-01 |
Anacor Pharmaceuticals Inc |
Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase.
|
WO2011019618A1
(en)
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011022502A1
(en)
|
2009-08-18 |
2011-02-24 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
US20110207701A1
(en)
*
|
2009-08-19 |
2011-08-25 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
JP5567136B2
(ja)
|
2009-09-08 |
2014-08-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
4−置換ピリジン−3−イル−カルボキサミド化合物及び使用方法
|
US20110124597A1
(en)
*
|
2009-09-25 |
2011-05-26 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(de)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
|
CA2776327A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Janssen Pharmaceutica Nv |
Proteasome inhibitors for treating cancer
|
WO2011049971A1
(en)
|
2009-10-20 |
2011-04-28 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
US20110212918A1
(en)
*
|
2009-11-11 |
2011-09-01 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
AU2010341530B2
(en)
|
2009-12-22 |
2016-03-10 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
CA2784425A1
(en)
|
2009-12-23 |
2011-06-30 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
MX343786B
(es)
|
2009-12-23 |
2016-11-22 |
Janssen Biotech Inc |
Diferenciacion de celulas madre embrionarias humanas.
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011094450A1
(en)
|
2010-01-27 |
2011-08-04 |
Anacor Pharmaceuticals, Inc |
Boron-containing small molecules
|
MA34133B1
(fr)
*
|
2010-03-01 |
2013-04-03 |
Onyx Therapeutics Inc |
Composes pour inhibiteurs de l'immunoproteasome
|
WO2011109279A2
(en)
*
|
2010-03-01 |
2011-09-09 |
Centocor Ortho Biotech Inc. |
Methods for purifying cells derived from pluripotent stem cells
|
AU2011227083B2
(en)
*
|
2010-03-18 |
2013-07-18 |
Innopharma, Inc. |
Stable bortezomib formulations
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
AP2012006482A0
(en)
|
2010-03-19 |
2012-10-31 |
Anacor Pharmacueticals Inc |
Boron-containing small molecules as anti-protozoalagent
|
EP2550362B1
(de)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv-glycoproteine und rekombinante vektoren
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
AR080863A1
(es)
|
2010-03-31 |
2012-05-16 |
Millennium Pharm Inc |
Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
|
MX2012011604A
(es)
|
2010-04-07 |
2013-02-27 |
Onyx Therapeutics Inc |
Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
CN102946879B
(zh)
|
2010-04-19 |
2015-04-22 |
尼基制药公司 |
一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
WO2011143299A2
(en)
|
2010-05-12 |
2011-11-17 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
CN105797168A
(zh)
|
2010-05-18 |
2016-07-27 |
天蓝制药公司 |
用于治疗自身免疫性疾病或其它疾病的组合物和方法
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
PL2611909T3
(pl)
|
2010-08-31 |
2018-05-30 |
Janssen Biotech, Inc |
Zróżnicowanie ludzkich embrionalnych komórek macierzystych
|
PL2611907T3
(pl)
|
2010-08-31 |
2016-11-30 |
|
Różnicowanie pluripotencjalnych komórek macierzystych
|
US9528090B2
(en)
|
2010-08-31 |
2016-12-27 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
EP2613788B1
(de)
|
2010-09-07 |
2017-06-21 |
Anacor Pharmaceuticals, Inc. |
Borhaltige kleine moleküle
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
WO2012047845A1
(en)
|
2010-10-05 |
2012-04-12 |
App Pharmaceuticals |
Bortezomib formulations stabilised with boric
|
ES2548256T3
(es)
|
2010-10-14 |
2015-10-15 |
Synthon Bv |
Proceso para la preparación de bortezomib y los intermedios para el proceso
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
TW201309303A
(zh)
*
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
US9272014B2
(en)
|
2011-03-29 |
2016-03-01 |
Texas Tech University System |
Galectin-3C combination therapy for human cancer
|
CN103502319B
(zh)
|
2011-03-31 |
2015-11-25 |
那野伽利阿株式会社 |
包含含有硼酸化合物的嵌段共聚物的医药组合物
|
RS57397B8
(sr)
|
2011-06-10 |
2020-01-31 |
Univ Oregon Health & Science |
Cmv glikoproteini i rekombinantni vektori
|
CA2833775A1
(en)
*
|
2011-06-22 |
2012-12-27 |
Cephalon, Inc. |
Proteasome inhibitors and processes for their preparation, purification and use
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
DK2742356T3
(en)
|
2011-08-11 |
2016-05-23 |
Janssen Pharmaceutica Nv |
CANCER TREATMENT PREDICTORS
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
DK2744332T3
(en)
|
2011-08-19 |
2017-01-16 |
Glaxo Group Ltd |
BENZOFURAN COMPOUNDS FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
PL2753334T3
(pl)
*
|
2011-08-30 |
2022-12-12 |
Trustees Of Tufts College |
Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
|
EP2568289A3
(de)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
JP6238900B2
(ja)
|
2011-10-28 |
2017-11-29 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
Nae阻害物質に対する応答のバイオマーカー
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
CN104126017A
(zh)
|
2011-11-11 |
2014-10-29 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
JP6397765B2
(ja)
|
2011-11-11 |
2018-09-26 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤に応答するバイオマーカー
|
ES2603632T3
(es)
|
2011-11-17 |
2017-02-28 |
The University Of Tokyo |
Copolímero en bloque que tiene un grupo ácido fenilborónico introducido en el mismo, y usos del mismo
|
CN105143446B
(zh)
|
2011-12-22 |
2020-11-03 |
詹森生物科技公司 |
人胚胎干细胞分化成单一激素胰岛素阳性细胞
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
WO2013110005A1
(en)
|
2012-01-18 |
2013-07-25 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
EP2810066B1
(de)
|
2012-01-24 |
2019-07-31 |
Millennium Pharmaceuticals, Inc. |
Verfahren zur behandlung von krebs
|
US10085987B2
(en)
|
2012-01-27 |
2018-10-02 |
Thomas Jefferson University |
MCT protein inhibitor-related prognostic and therapeutic methods
|
ES2735289T3
(es)
|
2012-02-08 |
2019-12-17 |
Igm Biosciences Inc |
Proteínas de unión a cdim y usos de las mismas
|
WO2013128419A2
(en)
|
2012-03-02 |
2013-09-06 |
Dr. Reddy's Laboratories Limited |
Pharmaceutical compositions comprising boronic acid compounds
|
RU2664467C2
(ru)
|
2012-03-07 |
2018-08-17 |
Янссен Байотек, Инк. |
Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
ES2690118T3
(es)
|
2012-06-08 |
2018-11-19 |
Janssen Biotech, Inc. |
Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
TW201414751A
(zh)
|
2012-07-09 |
2014-04-16 |
歐尼克斯治療公司 |
肽環氧酮蛋白酶抑制劑之前驅藥物
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
CN104822688A
(zh)
*
|
2012-09-11 |
2015-08-05 |
西普拉有限公司 |
制备硼替佐米的方法
|
US10662477B2
(en)
|
2012-10-01 |
2020-05-26 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
US9217001B2
(en)
|
2012-11-16 |
2015-12-22 |
Shilpa Medicare Limited |
Crystalline bortezomib process
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
CN111394298A
(zh)
|
2012-12-31 |
2020-07-10 |
詹森生物科技公司 |
使用hb9调节子使人胚胎干细胞分化为胰腺内分泌细胞的方法
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
CA2896655C
(en)
|
2012-12-31 |
2021-06-22 |
Janssen Biotech, Inc. |
Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
|
US10377989B2
(en)
|
2012-12-31 |
2019-08-13 |
Janssen Biotech, Inc. |
Methods for suspension cultures of human pluripotent stem cells
|
MX364895B
(es)
|
2013-03-13 |
2019-05-10 |
Forma Therapeutics Inc |
Nuevos compuestos y composiciones para la inhibicion de fasn.
|
IN2013MU01431A
(de)
|
2013-04-16 |
2015-06-26 |
Cipla Ltd |
|
EP2986290A4
(de)
|
2013-04-19 |
2017-01-04 |
Thomas Jefferson University |
Caveolin-1-verwandte verfahren zur behandlung von glioblastom mit temozolomid
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10478445B2
(en)
|
2013-07-03 |
2019-11-19 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
EP2848937A1
(de)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
|
JP2016531886A
(ja)
|
2013-10-03 |
2016-10-13 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
全身性エリテマトーデス及び/または狼瘡腎炎の予防または治療のための方法
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
WO2015076359A1
(ja)
*
|
2013-11-21 |
2015-05-28 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3633381A3
(de)
|
2013-12-05 |
2020-07-29 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur identifikation und behandlung von kachexie oder präkachexie
|
KR20160095035A
(ko)
|
2013-12-06 |
2016-08-10 |
노파르티스 아게 |
알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
|
CN111116622A
(zh)
|
2014-02-03 |
2020-05-08 |
俄亥俄州创新基金会 |
硼酸酯和其药物制剂
|
EP2910557A1
(de)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiomerenreine tetrasubstituierte Pyrrolidine als Gerüste für Proteasomhemmer und medizinische Anwendungen davon
|
JP6566936B2
(ja)
|
2014-05-08 |
2019-08-28 |
国立大学法人 東京大学 |
医薬組成物
|
BR112016026626A2
(pt)
|
2014-05-16 |
2017-08-15 |
Janssen Biotech Inc |
Uso de moléculas pequenas para melhorar a expressão de mafa em células pancreáticas endócrinas
|
SG10202003693RA
(en)
|
2014-05-20 |
2020-05-28 |
Millennium Pharm Inc |
Boron-containing proteasome inhibitors for use after primary cancer therapy
|
WO2016022955A1
(en)
|
2014-08-07 |
2016-02-11 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
CN107074885B
(zh)
*
|
2014-10-01 |
2020-11-27 |
默克专利股份公司 |
硼酸衍生物
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
US20180243217A1
(en)
|
2015-03-17 |
2018-08-30 |
Leon-Nanodrugs Gmbh |
Nanoparticles comprising a stabilized boronic acid compound
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
WO2016205790A2
(en)
|
2015-06-19 |
2016-12-22 |
Hanlin Scientific, Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
EP3120836A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Gebrauchsfertige bortezomib-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
*
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
KR20180073674A
(ko)
|
2015-11-02 |
2018-07-02 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
|
US11111296B2
(en)
|
2015-12-14 |
2021-09-07 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiac dysfunction
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
CA3025253A1
(en)
|
2016-06-21 |
2017-12-28 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
WO2017222914A1
(en)
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Carbocyclic prolinamide derivatives
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
EP3528794A1
(de)
|
2016-10-20 |
2019-08-28 |
Pfizer Inc |
Therapeutische teilchen mit peptidboronsäure- oder boronatesteresterverbindungen und verfahren zur herstellung und verwendung davon
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3583110A1
(de)
|
2017-02-17 |
2019-12-25 |
Fresenius Kabi Oncology Ltd |
Verbessertes verfahren zur herstellung von boronsäureestern
|
CA3054572A1
(en)
|
2017-02-28 |
2018-09-07 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
CN117338932A
(zh)
|
2017-08-23 |
2024-01-05 |
科智生命科学公司 |
自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌の組合せ治療
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
JP7333321B2
(ja)
*
|
2017-11-16 |
2023-08-24 |
プリンシピア バイオファーマ インコーポレイテッド |
免疫プロテアソーム阻害剤
|
EP3710458A1
(de)
|
2017-11-16 |
2020-09-23 |
Principia Biopharma Inc. |
Immunproteasominhibitoren
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
JP2021512165A
(ja)
|
2018-01-29 |
2021-05-13 |
コグノス・セラピューティクス・インコーポレイテッド |
ボルテゾミブの腫瘍内送達
|
WO2019178438A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of cancer
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
EP3873214A4
(de)
|
2018-10-29 |
2022-07-13 |
Forma Therapeutics, Inc. |
Feste formen von (4-(2-fluor-4-(1-methyl-1h-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanon
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119A
(zh)
*
|
2020-10-30 |
2022-05-06 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
EP4255920A2
(de)
*
|
2020-12-02 |
2023-10-11 |
Hoffman Technologies LLC |
Zusammensetzungen und verfahren zur modulation von krebs bei nichtmenschlichen säugern
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
US20230062279A1
(en)
|
2021-08-12 |
2023-03-02 |
Extrovis Ag |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|